Pay-For-Delay Antitrust Suits May Settle More Often After Jury Verdict For AstraZeneca
This article was originally published in The Pink Sheet Daily
Jury finds AstraZeneca’s Nexium patent infringement settlement with Ranbaxy was not antitrust violation; direct purchasers and third party payers claimed agreement was worth nearly $1 billion.
You may also be interested in...
California Supreme Court finds patents are ‘probablistic rather than ironclad,’ and outlines four-prong antitrust test that further complicates brand/generic deal making.
Teva plays it safe in $512 million agreement with direct purchasers, even though AstraZeneca won a jury verdict in similar suit, the first to go to trial since Supreme Court’s FTC v. Actavis decision.
Focused on $300 million in payments Cephalon made to generic firms to settle Provigil patent suits, case is second to proceed to trial since Supreme Court’s Actavis decision.